The dietary supplement industry is preparing for another round of regulatory change, and this time the three-letter acronym demanding attention is NDInew dietary ingredient. It may not sound as exciting as launching a tropical-flavored longevity gummy, but NDI compliance can determine whether an innovative ingredient reaches store shelves or becomes an expensive lesson in regulatory archaeology.

In 2026, the U.S. Food and Drug Administration placed several related initiatives on its agenda. The agency plans to finalize guidance explaining the identity and safety information expected in new dietary ingredient notifications. It is also developing ways to streamline reviews within the statutory 75-day period. Separately, FDA has listed a proposed rule that could determine that a specific ingredient is not excluded from the legal definition of a dietary supplement. As of July 25, 2026, that proposal remained under federal review and had not been published for public comment, so its exact terms were not yet available.

These actions do not amount to a wholesale rewrite of supplement law. However, they could influence ingredient development, safety dossiers, supplier contracts, product launch schedules, and the amount of coffee consumed by regulatory affairs teams.

What Is a New Dietary Ingredient?

Under the Dietary Supplement Health and Education Act of 1994, commonly called DSHEA, a new dietary ingredient is generally a dietary ingredient that was not marketed in the United States before October 15, 1994. The definition of a dietary ingredient includes vitamins, minerals, herbs and other botanicals, amino acids, certain dietary substances, and concentrates, metabolites, constituents, extracts, or combinations of those ingredients.

If a manufacturer or distributor intends to market a supplement containing an NDI, it generally must submit a premarket notification to FDA at least 75 days before introducing the product into interstate commerce. An exception may apply when the ingredient has been present in the food supply as an article used for food in a form that has not been chemically altered.

The notification must explain why a supplement containing the ingredient is reasonably expected to be safe under its proposed conditions of use. That means the dossier should address more than whether the ingredient sounds wholesome or appears beside a smiling leaf on the label. FDA may examine identity, manufacturing methods, specifications, history of use, proposed intake, toxicology, clinical evidence, vulnerable populations, and possible interactions.

An NDIN Is Not a Drug Approval

A new dietary ingredient notification, or NDIN, is a notification rather than a drug-style approval application. FDA does not determine that every supplement is effective before marketing, and an agency response does not erase the company’s continuing responsibility for safety, labeling, manufacturing quality, and legal compliance.

The distinction matters. A well-prepared notification can support lawful commercialization, but it is not a magical shield against future enforcement. A product can still create problems through adulteration, poor manufacturing practices, misleading claims, undisclosed formulation changes, or use levels that differ from those evaluated in the safety dossier.

What NDI Changes Is FDA Planning?

1. Final Guidance on Ingredient Identity and Safety

FDA has identified final guidance on NDI identity and safety information as a 2026 priority. The document is expected to explain more clearly what evidence companies should submit when identifying an ingredient and demonstrating that a supplement containing it is reasonably expected to be safe.

Identity is one of the most importantand occasionally underestimatedparts of an NDIN. A company cannot establish the safety of Ingredient A using studies conducted on Ingredient B merely because both have similar marketing names. Botanical species, plant parts, extraction solvents, fermentation organisms, purity levels, particle characteristics, chemical profiles, and manufacturing processes may all affect whether the studied material matches the commercial ingredient.

The forthcoming guidance may therefore encourage more disciplined use of specifications, validated analytical methods, certificates of analysis, manufacturing descriptions, contaminant limits, stability information, and batch-to-batch comparisons. FDA has said the NDIN process is its principal opportunity to evaluate the identity and safety of an NDI before consumers encounter it in supplements.

2. Faster and More Organized Notification Reviews

FDA also plans to develop methods for streamlining NDIN reviews and meeting the statutory 75-day timeline. The agency finalized procedural guidance in 2024 explaining who should submit a notification, how submissions should be organized, where they should be sent, and what happens after filing.

Better organization can reduce delays caused by missing information, inconsistent terminology, unreadable study reports, or a dossier that treats document navigation as an escape-room challenge. Companies should expect electronic submissions, logical indexing, searchable files, clear cross-references, and concise explanations of how each study supports the proposed conditions of use.

3. Greater Use of NDI Master Files

FDA issued draft guidance in 2024 describing NDI notification master files. A master file may contain confidential identity, manufacturing, or safety information submitted by an ingredient supplier. The owner can authorize another company to reference that information in an NDIN without giving the customer direct access to the proprietary material.

This approach could be especially useful when one branded ingredient is supplied to multiple supplement manufacturers. Instead of rebuilding the same technical package for every customer, a supplier can maintain a controlled body of evidence while permitting authorized references. The master-file concept may reduce duplication, protect trade secrets, and help FDA connect a finished product to the exact ingredient that was evaluated.

4. A Separate Rule Concerning an Ingredient Excluded From the Supplement Definition

FDA’s regulatory agenda also includes a proposed rule titled “Rulemaking to Provide by Regulation that an Ingredient Is Not Excluded From the Dietary Supplement Definition.” The wording points to a separate legal issue sometimes called the drug-exclusion or drug-preclusion provision.

Under federal law, an article that was first approved as a drugor publicly investigated as a drug under qualifying circumstancesmay be excluded from the dietary supplement definition if it was not previously marketed as a food or supplement. The law also gives FDA discretion to issue a regulation finding that such an article would nevertheless be lawful in dietary supplements.

The planned proposal appears to concern one specific ingredient, although the public agenda did not identify that ingredient. It should not be interpreted as a blanket invitation to place drug ingredients into capsules and add a “wellness” label. Even if FDA determines that an ingredient is not legally excluded, products containing it would still need to satisfy all other applicable requirements, including dietary-ingredient eligibility, NDI notification rules, safety standards, manufacturing controls, labeling rules, and restrictions on disease-treatment claims.

Why FDA Is Revisiting the Framework

The supplement marketplace has changed dramatically since DSHEA was enacted in 1994. Modern products may contain fermentation-derived substances, concentrated metabolites, novel probiotics, peptides, highly purified botanical constituents, or ingredients produced through technologies that did not fit neatly into the traditional vitamin-and-herb marketplace.

At a March 27, 2026 public meeting, FDA invited discussion about the scope of dietary supplement ingredients. Industry representatives argued that unclear interpretations can discourage responsible innovation and increase costs. Consumer advocates countered that expanding ingredient eligibility without strong evidence and oversight could expose shoppers to additional risks. In other words, one side sees a door that is too difficult to open, while the other worries somebody removed the hinges entirely.

Both concerns deserve attention. A predictable pathway can encourage companies to invest in testing and legitimate commercialization. At the same time, innovation is not a synonym for safety. A newly isolated, concentrated, chemically altered, or unusually dosed substance may produce effects that cannot be predicted from its presence in an ordinary food.

How the Planned NDI Rules Could Affect Supplement Companies

Ingredient Suppliers

Suppliers may need stronger documentation showing exactly what their ingredient is, how it is produced, how it differs from related materials, and whether its safety studies apply to each commercial batch. Suppliers that invest in defensible specifications, analytical methods, contaminant controls, stability testing, and master files may become more attractive partners.

Finished-Product Brands

Brands should not assume that a supplier’s marketing brochure proves NDI compliance. A finished-product company must understand whether the ingredient was marketed before October 15, 1994, whether it has been chemically altered, whether an NDIN was required, whether a notification actually covers the proposed dosage, and whether the product’s other ingredients change the safety analysis.

Contract Manufacturers

Contract manufacturers may face more detailed requests for traceability, manufacturing records, specifications, test methods, and confirmation that the material purchased matches the material described in an NDIN. A tiny change in extraction, fermentation, carrier composition, or purity can become a very large regulatory conversation.

Marketing Teams

NDI compliance does not authorize disease claims. FDA oversees supplement labeling, while the Federal Trade Commission evaluates advertising and requires competent support for health-related claims. A company can have an excellent safety dossier and still attract enforcement attention by advertising that its product treats arthritis, reverses dementia, cures insomnia, or performs another pharmaceutical miracle before breakfast.

Consumers

Better-defined identity and safety expectations could make it harder for weakly documented ingredients to enter the market and easier for responsible manufacturers to compete on quality. However, consumers should still remember that supplements are regulated differently from prescription and over-the-counter drugs. “Natural,” “clinically studied,” and “doctor formulated” are not substitutes for examining dosage, warnings, interactions, third-party testing, and the quality of the underlying evidence.

How Companies Can Prepare Now

1. Build an ingredient-status inventory. Classify every dietary ingredient as pre-DSHEA, new, exempt from notification, supported by an NDIN, or still requiring additional analysis.
2. Confirm the commercial material. Compare the sold ingredient with the material used in safety studies, including source, composition, manufacturing process, purity, and specifications.
3. Review conditions of use. Confirm that serving size, daily intake, duration, target population, warnings, and formulation match the evidence relied upon.
4. Strengthen supplier agreements. Require notification of manufacturing changes, specification changes, new safety findings, regulatory correspondence, and loss of authorization to reference a master file.
5. Create a change-control trigger. Regulatory review should occur before changing extraction solvents, plant parts, fermentation organisms, delivery systems, particle size, concentration, or dosage.
6. Separate safety from marketing. An ingredient may be reasonably expected to be safe without having adequate evidence for every benefit claimed in advertisements.
7. Monitor FDA publications. The proposed rule and final NDI guidance should be reviewed when published rather than interpreted through headlines, social posts, or an enthusiastic sales representative’s “trust me” slide.

Practical Industry Experience: Lessons From Real-World NDI Compliance

The following lessons reflect recurring compliance patterns across ingredient development, supplier qualification, notification preparation, and product launches. They are not personal anecdotes or legal advice, but they illustrate where supplement businesses commonly saveor losetime and money.

Experience 1: Start With Identity, Not With the Health Claim

A common mistake is to begin with an exciting scientific paper, design a product around the reported benefit, and investigate ingredient identity later. That order should be reversed. Teams should first define the exact commercial material: its source organism, botanical species and plant part, extraction or fermentation process, chemical fingerprint, purity, carriers, contaminants, and stability.

When the identity work is postponed, companies sometimes discover that the published study involved a different extract, a different ratio of active constituents, or a patented ingredient they are not actually buying. The safety and efficacy presentation may look impressive, but it is essentially wearing someone else’s name tag.

Experience 2: “Our Supplier Handles It” Is Not a Compliance Strategy

Brands frequently rely on assurances that an ingredient is “FDA compliant,” “grandfathered,” or “covered by an NDI.” Those phrases require verification. A responsible buyer asks for the NDIN number, FDA correspondence, right-of-reference documentation, specifications, manufacturing description, intended use levels, and an explanation of how the purchased material matches the notified ingredient.

The best supplier relationships are transparent without casually distributing trade secrets. A master file can help: the supplier protects confidential information, the brand receives authorization to reference it, and FDA can review the underlying data. Everyone gets what they need, and nobody has to email a proprietary manufacturing flowchart to twelve people named “Sales Team.”

Experience 3: Dosage Changes Can Break the Regulatory Bridge

An NDIN may support a specific daily intake for a defined population and duration. Marketing teams may later request a stronger serving because a competitor sells “double strength.” That seemingly simple change can alter the exposure calculation and move the product beyond the evidence supporting safety.

Companies with mature compliance systems treat dosage changes as technical changes, not merely label edits. Toxicologists, regulatory specialists, formulators, and quality personnel review the new exposure before packaging is ordered. This process is much cheaper than printing 100,000 labels and discovering that the recommended intake no longer matches the dossier.

Experience 4: A Clean Submission Is Easier to Defend

Strong NDINs tell a coherent story. The ingredient is clearly identified, manufacturing information explains how it is made, specifications define acceptable material, analytical data show that batches meet those specifications, and safety evidence supports the exact proposed conditions of use.

Weak submissions often contain plenty of pages but little alignment. One document uses a trade name, another uses a chemical name, a third describes a different concentration, and the proposed label introduces a serving level not discussed anywhere else. More pages do not automatically create more certainty. Sometimes they simply create a taller pile of uncertainty.

Experience 5: Plan the Regulatory Path Before Announcing the Launch

Product teams work more efficiently when regulatory classification begins during ingredient selection. The company can determine whether the substance qualifies as a dietary ingredient, whether the drug-exclusion provision may apply, whether an NDIN is required, what studies are missing, and how the 75-day review period affects the launch schedule.

By contrast, announcing a launch date before resolving ingredient status creates pressure to interpret every ambiguity in the company’s favor. That is how cautious scientific questions become urgent commercial emergencies. A regulatory pathway mapped early may feel slower during development, but it usually produces a faster and more defensible launch.

Conclusion

FDA’s planned NDI actions could bring clearer expectations to one of the supplement industry’s most complicated regulatory areas. Final guidance on ingredient identity and safety may improve notification quality, while streamlined reviews and master files could reduce unnecessary duplication. The separate proposed rule concerning an ingredient excluded from the dietary supplement definition may also demonstrate how FDA uses its statutory discretion when drug development and supplement marketing overlap.

The most important lesson is that ingredient eligibility, NDI status, safety, manufacturing quality, and marketing claims are separate questions. Passing one gate does not automatically open the others. Companies that document each decision, verify supplier representations, control formulation changes, and prepare evidence before launch will be in the strongest position when the new policies arrive.